510 related articles for article (PubMed ID: 23412770)
41. Cytoplasmic CXCR4 high-expression exhibits distinct poor clinicopathological characteristics and predicts poor prognosis in triple-negative breast cancer.
Chen HW; Du CW; Wei XL; Khoo US; Zhang GJ
Curr Mol Med; 2013 Mar; 13(3):410-6. PubMed ID: 23331013
[TBL] [Abstract][Full Text] [Related]
42. Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal cells in pancreatic cancer.
Galván JA; Zlobec I; Wartenberg M; Lugli A; Gloor B; Perren A; Karamitopoulou E
Br J Cancer; 2015 Jun; 112(12):1944-50. PubMed ID: 25989272
[TBL] [Abstract][Full Text] [Related]
43. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
[TBL] [Abstract][Full Text] [Related]
44. Expression of topoisomerase II-α in triple negative breast cancer.
Mrklić I; Pogorelić Z; Ćapkun V; Tomić S
Appl Immunohistochem Mol Morphol; 2014 Mar; 22(3):182-7. PubMed ID: 23702653
[TBL] [Abstract][Full Text] [Related]
45. ABO blood type/Rh factor and the incidence and outcomes for patients with triple-negative breast cancer.
Yu J; Gao F; Klimberg VS; Margenthaler JA
Ann Surg Oncol; 2012 Oct; 19(10):3159-64. PubMed ID: 22878611
[TBL] [Abstract][Full Text] [Related]
46. Differences in autophagy-related activity by molecular subtype in triple-negative breast cancer.
Kim S; Jung WH; Koo JS
Tumour Biol; 2012 Oct; 33(5):1681-94. PubMed ID: 22638807
[TBL] [Abstract][Full Text] [Related]
47. Clinical significance of basal-like subtype in triple-negative breast cancer.
Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
[TBL] [Abstract][Full Text] [Related]
48. [Triple-negative breast cancer: analysis of patients diagnosed and/or treated at the Masaryk Memorial Cancer Institute between 2004 and 2009].
Svoboda M; Navrátil J; Fabian P; Palácová M; Gombošová J; Slámová L; Princ D; Syptáková B; Kudláček A; Bílek O; Pospíšil P; Kazda T; Grell P; Poprach A; Selingerová I; Nenutil R; Juráček J; Héžová R; Slabý O; Vyzula R
Klin Onkol; 2012; 25(3):188-98. PubMed ID: 22724568
[TBL] [Abstract][Full Text] [Related]
49. Nuclear localization of GLI1 and elevated expression of FOXC2 in breast cancer is associated with the basal-like phenotype.
Li Y; Yang W; Yang Q; Zhou S
Histol Histopathol; 2012 Apr; 27(4):475-84. PubMed ID: 22374725
[TBL] [Abstract][Full Text] [Related]
50. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
[TBL] [Abstract][Full Text] [Related]
51. Calpain system protein expression in basal-like and triple-negative invasive breast cancer.
Storr SJ; Lee KW; Woolston CM; Safuan S; Green AR; Macmillan RD; Benhasouna A; Parr T; Ellis IO; Martin SG
Ann Oncol; 2012 Sep; 23(9):2289-2296. PubMed ID: 22745213
[TBL] [Abstract][Full Text] [Related]
52. Ductal carcinoma in situ associated with triple negative invasive breast cancer: evidence for a precursor-product relationship.
Thike AA; Iqbal J; Cheok PY; Tse GM; Tan PH
J Clin Pathol; 2013 Aug; 66(8):665-70. PubMed ID: 23539741
[TBL] [Abstract][Full Text] [Related]
53. [Clinicopathologic features and prognosis of triple negative breast cancer].
Zhou T; Yang L; Ma GM; Li CX; Bai Y; Zhao JA; Wang XL; Geng CZ
Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(32):2261-4. PubMed ID: 20095338
[TBL] [Abstract][Full Text] [Related]
54. The GRHL2/ZEB Feedback Loop-A Key Axis in the Regulation of EMT in Breast Cancer.
Mooney SM; Talebian V; Jolly MK; Jia D; Gromala M; Levine H; McConkey BJ
J Cell Biochem; 2017 Sep; 118(9):2559-2570. PubMed ID: 28266048
[TBL] [Abstract][Full Text] [Related]
55. Role of PRL-3, Snail, Cytokeratin and Vimentin expression in epithelial mesenchymal transition in breast carcinoma.
Patel NA; Patel PS; Vora HH
Breast Dis; 2015; 35(2):113-27. PubMed ID: 25547164
[TBL] [Abstract][Full Text] [Related]
56. ZEB1 promotes epithelial-mesenchymal transition in cervical cancer metastasis.
Ran J; Lin DL; Wu RF; Chen QH; Huang HP; Qiu NX; Quan S
Fertil Steril; 2015 Jun; 103(6):1606-14.e1-2. PubMed ID: 25963537
[TBL] [Abstract][Full Text] [Related]
57. Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance.
Mohammed RA; Ellis IO; Mahmmod AM; Hawkes EC; Green AR; Rakha EA; Martin SG
Mod Pathol; 2011 Jun; 24(6):774-85. PubMed ID: 21378756
[TBL] [Abstract][Full Text] [Related]
58. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
Cheang MC; Voduc D; Bajdik C; Leung S; McKinney S; Chia SK; Perou CM; Nielsen TO
Clin Cancer Res; 2008 Mar; 14(5):1368-76. PubMed ID: 18316557
[TBL] [Abstract][Full Text] [Related]
59. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.
Jin MS; Hyun CL; Park IA; Kim JY; Chung YR; Im SA; Lee KH; Moon HG; Ryu HS
Tumour Biol; 2016 Apr; 37(4):4743-53. PubMed ID: 26515337
[TBL] [Abstract][Full Text] [Related]
60. Transcription factors associated with epithelial-mesenchymal transition and cancer stem cells in the tumor centre and margin of invasive breast cancer.
Alkatout I; Wiedermann M; Bauer M; Wenners A; Jonat W; Klapper W
Exp Mol Pathol; 2013 Feb; 94(1):168-73. PubMed ID: 22985790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
